Boiron (FRA:BON) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Boiron LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Boiron's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.01.

Boiron's long-term debt to total assets ratio declined from Dec. 2022 (0.02) to Dec. 2023 (0.01). It may suggest that Boiron is progressively becoming less dependent on debt to grow their business.

Boiron LT-Debt-to-Total-Asset Historical Data

The historical data trend for Boiron's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron LT-Debt-to-Total-Asset Chart

Boiron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.02

0.01

Boiron Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.03	0.02	0.01	0.01

Boiron LT-Debt-to-Total-Asset Calculation

Boiron's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	6.645	/	590.201
	=	0.01

Boiron's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	6.645	/	590.201
	=	0.01

Boiron (FRA:BON) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Boiron LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Boiron's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Boiron (FRA:BON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BOIRF:USA BOI:France BON:Germany

Address

2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510

Website

http://www.boiron.com

Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.